Hairy cell leukemia is a rare , slow growing blood cancer in which there is excessive production of unripened and non - functional B complex lymphocyte . The condition is named after hairy appearance of these cells when watch under a microscope . These abnormal cells are know as leukemic cells . Hairy cell leukemia gets worse slowly or does not get worse at all . It affects all blood cell include crimson lineage cells , white blood cells and platelets as these leukemic cells build up inbone marrowand blood leading toanemia , thrombocytopeniaand leucopenia . Pancytopenia may lead to increased susceptibility to infection , anemia and easy bleeding .
The etiology of hairy cell cancer of the blood is still unidentified , but it has been linked to genetic genetic mutation . man in the age radical of 40 to 70 are five times more susceptible to this eccentric ofblood cancer . They may salute with signs of infection , tiredness , painfulness below the rib , abdominal pain(due tosplenomegaly),frequent pyrexia , brusqueness of breath , unexplainedweight loss , easy repletion , collocate in neck , axilla , stomach or bulwark and well-to-do bruising / haemorrhage .
Can Hairy Cell Leukemia Be Cured?
Although , hairy cell leucaemia is a uncommon condition , it is a successfully treated disease with very unspoiled prognosis and excellent survival rate of about 10 years after remittance of the disease . After remission , the patients dwell a healthy normal life history with regular monitoring of the status . Since hirsute cell leukemia is a very rare condition , it is not extensively canvass , so currently there is no lasting cure for it ; however , the current treatment aim at controlling the disease advance with increased survival rate of the patients .
Hairy cell leukemia is diagnosed with the assistance of stock test or bone marrow trial along withultrasoundorCT scanto look for involvement of any other torso piece . After diagnosis , immediate intervention is not required in all the patients and these patients can be monitored until intervention is needed . Symptomatic treatment is given to patients suffering from the disease . Often treatment is necessitate for frequent infections along with febricity due to lessening in blanched blood cell count .
For the last three decades , purine analogues ( pentostatin and cladribine ) have been the basis of hairy cell leukemia treatment . They are extremely effective at verify the disease and inducing 90 - 95 % complete remission of sin pace and a survival pace of about 10 years .
Pentostatin is dispense intravenously every 2 to 3 weeks for up to 6 months until remission is achieved . Kidney function tryout along with creatinine levels is monitored as this drug is excrete through kidneys .
Cladribine can be given either as a 7 day uninterrupted IV infusion , daily / hebdomadal IV infusions of 6 DoS or as subcutaneous injections for 5 consecutive days . Along with pentostatin and cladribine , since they suppress resistant arrangement , thus increasing chance of contagion , antibiotics / antivirals are prescribed in modest doses to cut down the jeopardy of infection .
Other treatment option let in interferon - A and rituximab . Rituximab is used in combination with pentostatin or cladribine in cases of lapsing . Interferon - A is preferred in patients with a diagnosing of infection , either alone or in compounding therapy with cladribine or pentostatin .
Splenectomyis rarely do with the coming and success rate of current drugs . However , it is still perform in cases of excessive splenomegaly and blood loading .
Monitoring of Patients with Hairy Cell Leukemia
even monitoring of patients is expect in hairy cell leukemia and blood counting start to turn over normal levels within few weeks of treatment . The response of treatment is appraise by blood trial and bone marrow test . Bone marrow exam is an unpleasant experience , but is of great value in assess the discourse principle , progression and remittal . About 40 % of patients reverting , which is noted by diminish blood numeration and confirmed by bone vegetable marrow examination . Retreatment is also successful in hairy cell leukemia cases , but with shorter full point of remission . About 30 % of patients have a prospect of developing junior-grade cancers after being treat for hairy cell leukemia , so long term watch up of patients is quite necessary .
Also Read :
